Clinical inquiries. Should patients receive 23-valent pneumococcal vaccination more than once?
No patient-oriented evidence supports pneumococcal revaccination of any patient (high-risk or otherwise). Antibody levels may be augmented by revaccination; however, the clinical efficacy of revaccination, even among high-risk patients, is unknown. Revaccination is recommended by the Advisory Committee on Immunization Practices (ACIP) in certain circumstances (strength of recommendation [SOR]: C, expert opinion based on physiology/bench research). Revaccination once appears to be safe, especially if provided 5 years or more after primary vaccination (SOR: B, based upon consistent results of cohort studies and nonrandomized prospective trials).
Whiteside
John
J
Department of Family Medicine, Mayo Clinic, Scottsdale, AZ USA.
Grover
Michael
M
Hitchcock
Kristin
K
Kim
Richard
R
D002986:Clinical Trials as Topic; D006801:Humans; D008586:Meningitis, Pneumococcal / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000276:immunology; D014481:United States / Q000453:epidemiology
D022242:Pneumococcal Vaccines